REG - Adv Medical Solutns. - Half Year Trading Update

Advanced Medical SolutionsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250715:nRSO0118Ra&default-theme=true

RNS Number : 0118R  Advanced Medical Solutions Grp PLC  15 July 2025

15 July 2025

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

Half Year Trading Update

 

~ Strong performance, integrations progressing well ~

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a world-leading
specialist in tissue-healing technologies, today announces a trading update
for the six months ended 30 June 2025.

Strong underlying momentum in our core surgical product portfolio has
continued to drive robust growth during the first half of the year. The
integration of Peters Surgical and Syntacoll is progressing well with initial
commercial synergies already contributing positively to surgical sales growth.
As anticipated, the restructuring of Woundcare was successfully completed by
the end of March, resulting in improved margins for that business from the
second quarter.

 

The Group expects to report Half Year 2025 revenues of approximately £110
million (H1 2024: £68.0 million), and adjusted EBITDA of £24.0 - £24.5
million (H1 2024: £18.2 million). This performance remains in line with
expectations and, underpinned by continued momentum in the business, the Board
continues to be confident in meeting full-year consensus forecasts.

 

The Group expects to announce its interim results on 17 September 2025.

 

Chris Meredith, Chief Executive Officer of AMS, said: "One year on from
successfully completing the acquisition of Peters Surgical, it is a good
moment to take stock of the excellent integration progress to date, both
operationally and in terms of strategic alignment. On the commercial front, we
have been pleased to see early synergies already beginning to translate into
top-line growth. We remain fully focused on delivering longer-term,
significant synergies as integration continues. In parallel, our newly
restructured Woundcare business has entered a new phase and is now making a
steady contribution to the Group. Underpinned by our core surgical product
portfolio, we are pressing ahead to deliver strong growth at the Group level."

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

Advanced Medical Solutions Group plc
                                    Tel:
+44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

 

ICR
Healthcare
Tel: +44 (0) 20 3709 5700

Mary-Jane Elliott / Lucy Featherstone
 
AMS@icrhealthcare.com (mailto:AMS@icrhealthcare.com)

 

Investec Bank PLC (NOMAD & Joint
Broker)
Tel: +44 (0) 20 7597 5970

Gary Clarence / David Anderson

 

Berenberg (Joint
Broker)
Tel: +44 (0)20 3207 7800

Toby Flaux / Detlir Elezi / Yasmina Benchekroun

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

 

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®, RESORBA®,
LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G®. AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal® brand as well as under white
label. Since 2019, the Group has made seven acquisitions: Sealantis, an
Israeli developer of innovative internal sealants, Biomatlante, a French
developer and manufacturer of surgical biomaterials, Raleigh, a leading UK
coater and converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish tissue
adhesives specialist, Syntacoll, a German specialist in collagen-based
absorbable surgical implants and Peters Surgical, a global provider of
specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate
devices.

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands,
Thailand, India, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France, Poland,
Benelux, India, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Ireland, Germany, France and Israel. Established in
1991, the Group has more than 1,500 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com) .

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFLFITDDISLIE